Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company focused on the discovery, design, and development of innovative peptide-based medicines. Founded in 1998 and headquartered in Søborg, Denmark, it leverages over 25 years of expertise in peptide research to address unmet medical needs in obesity, rare diseases, and chronic inflammation. The company engineers peptides—short chains of amino acids—to enhance biological activity, extend duration of action, and improve stability, creating therapies from endogenous human peptides, animal venoms, and custom unnatural amino acids. Its portfolio includes marketed products like Zegalogue (dasiglucagon) for severe hypoglycemia and pipeline candidates such as petrelintide, a long-acting amylin analog for weight loss; glepaglutide for short bowel syndrome; and survodutide, licensed to Boehringer Ingelheim for obesity. Zealand Pharma pursues global partnerships, employs over 350 people primarily in R&D, and maintains a robust pipeline with more than eight investigational candidates, positioning it as a leader in peptide therapeutics for metabolic, gastrointestinal, and inflammatory conditions.